NCT06940102 - Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions

CachexiaDigestive System CancerGastric CancerColorectal CancerHepatocellular Carcinoma

Interventions

DRUG

Nano-crystalline Megestrol Acetate Oral Suspension

Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day)

DRUG

TKI-Based Therapy

Trial Locations (2)

RECRUITING

General Hospital of Northern Theater Command, Shenyang

RECRUITING

Liaoning Cancer Hospital, Shenyang

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY